Search results
Results from the WOW.Com Content Network
Dose-dependent anxiolytic effects, [13] with anxiogenic effects at high doses; Appetite stimulation [13] [14] Anti-nausea [13] [14] In combination with CBD, potential efficacy in treatment of spasticity, neuropathic pain and muscle spasticity (see Sativex: THC-containing therapeutic approved in Europe as treatment for Multiple Sclerosis)
The aromatic terpenoids begin to vaporize at 126.0 °C (258.8 °F), but the more bioactive tetrahydrocannabinol (THC), and other cannabinoids also found in cannabis (often legally sold as cannabinoid isolates) like cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), do not vaporize until near their respective boiling ...
Acclaimed for relieving chronic pain, some researchers conclude that the evidence is insufficient to determine the effectiveness of CBD in pain relief, primarily due to the challenging access to pure CBD. [41] CBD oil is used for massage therapy as a substitute for body oil and for its health benefits. [42]
In THC, CBD, and CBN, this side-chain is a pentyl (5-carbon) chain. In the most common homologue, the pentyl chain is replaced with a propyl (3-carbon) chain. Cannabinoids with the propyl side chain are named using the suffix varin and are designated THCV, CBDV, or CBNV, while those with the heptyl side chain are named using the suffix phorol ...
A 2022 review concluded that "oral, synthetic cannabis products with high THC-to-CBD ratios and sublingual, extracted cannabis products with comparable THC-to-CBD ratios may be associated with short-term improvements in chronic pain and increased risk for dizziness and sedation." [164]
Nabilone can increase – rather than decrease – postoperative pain. [citation needed] In the treatment of fibromyalgia, adverse effects limit the useful dose. [4]Adverse effects of nabilone include, but are not limited to: dizziness/vertigo, euphoria, drowsiness, dry mouth, ataxia, sleep disturbance, headache, nausea, disorientation, depersonalization, hallucinations, and asthenia.
Each spray delivers a dose of 2.7 mg THC and 2.5 mg CBD. In 2003, GW Pharmaceuticals partnered with Bayer to market the drug under the brand name Sativex. In 2011, GW licensed the rights to commercialise nabiximols to Novartis for Asia (excluding China and Japan ), Africa and the Middle East (excluding Israel ).
CBD is a very low-affinity CB 1 ligand, that can nevertheless affect CB 1 receptor activity in vivo in an indirect manner, while THCV is a high-affinity CB 1 receptor ligand and potent antagonist in vitro and yet only occasionally produces effects in vivo resulting from CB 1 receptor antagonism.